"Designing Growth Strategies is in our DNA"

Canada Prostate Cancer Hormone Therapy Market Size, Share & Industry Analysis, By Drug Class (Gonadotropin Releasing Hormone Agonist {By Product Type [Lupron, Eligard, & Zoladex], By Route of Administration [Oral and Parenteral]}, Gonadotropin-Releasing Hormone Receptor Antagonist {By Product Type [FIRMAGON, ORGOVYX, & Others], By Route of Administration [Oral & Parenteral], Androgen Receptor Inhibitors [Oral & Parenteral], and Others, By Disease State (Metastatic Castration-Resistant Prostate Cancer, & Others), By Distribution Channel, and Regional Forecast, 2025-2032

Last Updated: December 24, 2025 | Format: PDF | Report ID: FBI114940

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Epidemiology of Prostate Cancer in Canada, 2024 and 2025 
    2. Pipeline Analysis, By Key Players 
    3. Overview: Alternative Therapies to Hormonal Therapy for Prostate Cancer Treatment in Canada
    4. Overview: Regulatory and Reimbursement Scenario (By Key Provinces/Canada Level) 
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    6. Advances in Prostate Cancer Hormonal Therapies (ARPIs, etc.): Overview
  5. Canada Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Gonadotropin Releasing Hormone (GnRH) Agonist
        1. By Product Type
          1. Lupron
          2. Eligard
          3. Zoladex
          4. Others
        2. By Route of Administration
          1. Oral
          2. Parenteral
      2. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
        1. By Product Type
          1. FIRMAGON
          2. ORGOVYX
          3. Others
        2. By Route of Administration
          1. Oral
          2. Parenteral
      3. Androgen Receptor Inhibitors
        1. Oral
        2. Parenteral
      4. Others
        1. Oral
        2. Parenteral
    2. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer 
      2. Non-Metastatic Castration-Resistant Prostate Cancer
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. Canada Market Share Analysis (Value) (2024)
    2. Canada Market Share Analysis (Volume) (2024)
    3. Company Profiles (Overview, Drug Class, Swot Analysis, Recent Developments, Strategies, Financials (Based On Availability)
      1. Astellas Pharma Inc.
      2. Johnson & Johnson 
      3. Bayer AG
      4. AbbVie Inc. 
      5. Ferring
      6. Tolmar, Inc.
      7. Knight Therapeutics Inc.
      8. TerSera Therapeutics LLC.
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Epidemiology of Prostate Cancer in Canada, 2024 and 2025 
    2. Pipeline Analysis, By Key Players 
    3. Overview: Alternative Therapies to Hormonal Therapy for Prostate Cancer Treatment in Canada
    4. Overview: Regulatory and Reimbursement Scenario (By Key Provinces/Canada Level) 
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    6. Advances in Prostate Cancer Hormonal Therapies (ARPIs, etc.): Overview
  5. Canada Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights, and Forecast – By Drug Class
      1. Gonadotropin Releasing Hormone (GnRH) Agonist
        1. By Product Type
          1. Lupron
          2. Eligard
          3. Zoladex
          4. Others
        2. By Route of Administration
          1. Oral
          2. Parenteral
      2. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
        1. By Product Type
          1. FIRMAGON
          2. ORGOVYX
          3. Others
        2. By Route of Administration
          1. Oral
          2. Parenteral
      3. Androgen Receptor Inhibitors
        1. Oral
        2. Parenteral
      4. Others
        1. Oral
        2. Parenteral
    2. Market Analysis, Insights and Forecast – By Disease State
      1. Metastatic Castration-Resistant Prostate Cancer 
      2. Non-Metastatic Castration-Resistant Prostate Cancer
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. Canada Market Share Analysis (Value) (2024)
    2. Canada Market Share Analysis (Volume) (2024)
    3. Company Profiles (Overview, Drug Class, Swot Analysis, Recent Developments, Strategies, Financials (Based On Availability)
      1. Astellas Pharma Inc.
      2. Johnson & Johnson 
      3. Bayer AG
      4. AbbVie Inc. 
      5. Ferring
      6. Tolmar, Inc.
      7. Knight Therapeutics Inc.
      8. TerSera Therapeutics LLC.
Read Less

Table 01: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Drug Class, 2019–2032

Table 02: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Gonadotropin Releasing Hormone (GnRH) Agonist, By Product Type, 2019–2032

Table 03: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Gonadotropin Releasing Hormone (GnRH) Agonist, By Route of Administration, 2019–2032

Table 04: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, By Product Type, 2019–2032

Table 05: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, By Route of Administration, 2019–2032

Table 06: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Androgen Receptor Inhibitors, By Route of Administration, 2019–2032

Table 07: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Others, By Route of Administration, 2019–2032

Table 08: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Disease State, 2019–2032

Table 09: Canada Prostate Cancer Hormone Therapy Market Revenue (USD million) Forecast, By Distribution Channel, 2019–2032

Figure 01: Canada Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD million, %), By Drug Class, 2024 & 2032

Figure 02: Canada Prostate Cancer Hormone Therapy Market Value Share (%), By Drug Class, 2024 & 2032

Figure 03: Canada Prostate Cancer Hormone Therapy Market Value Share (%), By Disease State, 2024 & 2032

Figure 04: Canada Prostate Cancer Hormone Therapy Market Value Share (%), By Distribution Channel, 2024 & 2032

Figure 05: Canada Prostate Cancer Hormone Therapy Market Share (%) (in Value), 2024

Figure 06: Canada Prostate Cancer Hormone Therapy Market Share (%) (in Volume), 2024

Canada Prostate Cancer Hormone Therapy Market
  • 2019-2032
  • 2024
  • 2019-2023
  • 99
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports